Report Detail
Global Donafenib Tosylate Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032
- RnM4706191 |
- 09 June, 2026 |
- Global |
- 85 Pages |
- GIR |
- Pharma & Healthcare
According to our (Global Info Research) latest study, the global Donafenib Tosylate market size was valued at US$ 36.42 million in 2025 and is forecast to a readjusted size of US$ 97 million by 2032 with a CAGR of 5.9% during review period.
In 2025, global production of donafenib tosilate reached approximately 32,000 units.Donafenib Tosylate is an orally administered small-molecule multi-target tyrosine kinase inhibitor (TKI), primarily used for the treatment of malignant tumors such as hepatocellular carcinoma. It is the tosylate form of donafenib and exerts its effects by inhibiting multiple kinases associated with tumor growth and angiogenesis, including RAF kinases, VEGFR, and PDGFR, thereby blocking tumor cell proliferation and tumor angiogenesis.
Compared with traditional drugs of the same class, donafenib tosylate maintains antitumor activity while achieving improved safety and tolerability to a certain extent through structural optimization. As one of the domestically developed targeted anticancer drugs in China, it has been approved for first-line treatment of advanced hepatocellular carcinoma and demonstrates significant clinical value and promising development prospects.
Donafenib Tosylate, as a domestically developed small-molecule multi-target tyrosine kinase inhibitor in China, is primarily positioned in the hepatocellular carcinoma (HCC) treatment market. Globally, the incidence and mortality of liver cancer remain high, particularly in Asia-Pacific regions such as China, where the large patient population provides a stable and continuously growing market demand for this drug. From a competitive perspective, targeted therapies such as sorafenib and lenvatinib have already captured a certain market share; however, with increasing clinical demands for improved efficacy and safety, next-generation drugs are gaining attention. Clinical studies have demonstrated that donafenib tosylate offers favorable survival benefits and tolerability, giving it a competitive advantage in the first-line treatment setting.
In the Chinese market, government support for innovative drugs, improvements in reimbursement access, and the implementation of centralized procurement policies are expected to enhance drug accessibility and promote market penetration. Meanwhile, with the advancement of precision medicine and the continuous standardization of clinical treatment practices, targeted therapies with differentiated advantages are more likely to gain acceptance among physicians and patients. From a global perspective, the demand for targeted cancer therapies continues to grow; however, entry into mature markets such as Europe and the United States will still require further clinical evidence and regulatory approvals.
This report is a detailed and comprehensive analysis for global Donafenib Tosylate market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Donafenib Tosylate market size and forecasts, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Donafenib Tosylate market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Donafenib Tosylate market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Donafenib Tosylate market shares of main players, shipments in revenue ($ Million), sales quantity (Units), and ASP (US$/Unit), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Donafenib Tosylate
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Donafenib Tosylate market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Suzhou Zelgen Biopharmaceuticals, Zhejiang Apeloa Kangyu Pharmaceutical, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Donafenib Tosylate market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
200 mg
300 mg
Market segment by Sales Channels
Hospital
Retail
Online
Market segment by Dosage Form
Tablets
Powder
Market segment by Application
Hepatocellular Carcinoma (HCC)
Inhibit tumor Cell Proliferation
Inhibit tumor Angiogenesis
Others
Major players covered
Suzhou Zelgen Biopharmaceuticals
Zhejiang Apeloa Kangyu Pharmaceutical
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Donafenib Tosylate product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Donafenib Tosylate, with price, sales quantity, revenue, and global market share of Donafenib Tosylate from 2021 to 2026.
Chapter 3, the Donafenib Tosylate competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Donafenib Tosylate breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Donafenib Tosylate market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Donafenib Tosylate.
Chapter 14 and 15, to describe Donafenib Tosylate sales channel, distributors, customers, research findings and conclusion.
1 Market Overview
- 1.1 Product Overview and Scope
- 1.2 Market Estimation Caveats and Base Year
- 1.3 Market Analysis by Type
- 1.3.1 Overview: Global Donafenib Tosylate Consumption Value by Type: 2021 Versus 2025 Versus 2032
- 1.3.2 200 mg
- 1.3.3 300 mg
- 1.4 Market Analysis by Sales Channels
- 1.4.1 Overview: Global Donafenib Tosylate Consumption Value by Sales Channels: 2021 Versus 2025 Versus 2032
- 1.4.2 Hospital
- 1.4.3 Retail
- 1.4.4 Online
- 1.5 Market Analysis by Dosage Form
- 1.5.1 Overview: Global Donafenib Tosylate Consumption Value by Dosage Form: 2021 Versus 2025 Versus 2032
- 1.5.2 Tablets
- 1.5.3 Powder
- 1.6 Market Analysis by Application
- 1.6.1 Overview: Global Donafenib Tosylate Consumption Value by Application: 2021 Versus 2025 Versus 2032
- 1.6.2 Hepatocellular Carcinoma (HCC)
- 1.6.3 Inhibit tumor Cell Proliferation
- 1.6.4 Inhibit tumor Angiogenesis
- 1.6.5 Others
- 1.7 Global Donafenib Tosylate Market Size & Forecast
- 1.7.1 Global Donafenib Tosylate Consumption Value (2021 & 2025 & 2032)
- 1.7.2 Global Donafenib Tosylate Sales Quantity (2021-2032)
- 1.7.3 Global Donafenib Tosylate Average Price (2021-2032)
2 Manufacturers Profiles
- 2.1 Suzhou Zelgen Biopharmaceuticals
- 2.1.1 Suzhou Zelgen Biopharmaceuticals Details
- 2.1.2 Suzhou Zelgen Biopharmaceuticals Major Business
- 2.1.3 Suzhou Zelgen Biopharmaceuticals Donafenib Tosylate Product and Services
- 2.1.4 Suzhou Zelgen Biopharmaceuticals Donafenib Tosylate Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.1.5 Suzhou Zelgen Biopharmaceuticals Recent Developments/Updates
- 2.2 Zhejiang Apeloa Kangyu Pharmaceutical
- 2.2.1 Zhejiang Apeloa Kangyu Pharmaceutical Details
- 2.2.2 Zhejiang Apeloa Kangyu Pharmaceutical Major Business
- 2.2.3 Zhejiang Apeloa Kangyu Pharmaceutical Donafenib Tosylate Product and Services
- 2.2.4 Zhejiang Apeloa Kangyu Pharmaceutical Donafenib Tosylate Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.2.5 Zhejiang Apeloa Kangyu Pharmaceutical Recent Developments/Updates
3 Competitive Environment: Donafenib Tosylate by Manufacturer
- 3.1 Global Donafenib Tosylate Sales Quantity by Manufacturer (2021-2026)
- 3.2 Global Donafenib Tosylate Revenue by Manufacturer (2021-2026)
- 3.3 Global Donafenib Tosylate Average Price by Manufacturer (2021-2026)
- 3.4 Market Share Analysis (2025)
- 3.4.1 Producer Shipments of Donafenib Tosylate by Manufacturer Revenue ($MM) and Market Share (%): 2025
- 3.4.2 Top 3 Donafenib Tosylate Manufacturer Market Share in 2025
- 3.4.3 Top 6 Donafenib Tosylate Manufacturer Market Share in 2025
- 3.5 Donafenib Tosylate Market: Overall Company Footprint Analysis
- 3.5.1 Donafenib Tosylate Market: Region Footprint
- 3.5.2 Donafenib Tosylate Market: Company Product Type Footprint
- 3.5.3 Donafenib Tosylate Market: Company Product Application Footprint
- 3.6 New Market Entrants and Barriers to Market Entry
- 3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
- 4.1 Global Donafenib Tosylate Market Size by Region
- 4.1.1 Global Donafenib Tosylate Sales Quantity by Region (2021-2032)
- 4.1.2 Global Donafenib Tosylate Consumption Value by Region (2021-2032)
- 4.1.3 Global Donafenib Tosylate Average Price by Region (2021-2032)
- 4.2 North America Donafenib Tosylate Consumption Value (2021-2032)
- 4.3 Europe Donafenib Tosylate Consumption Value (2021-2032)
- 4.4 Asia-Pacific Donafenib Tosylate Consumption Value (2021-2032)
- 4.5 South America Donafenib Tosylate Consumption Value (2021-2032)
- 4.6 Middle East & Africa Donafenib Tosylate Consumption Value (2021-2032)
5 Market Segment by Type
- 5.1 Global Donafenib Tosylate Sales Quantity by Type (2021-2032)
- 5.2 Global Donafenib Tosylate Consumption Value by Type (2021-2032)
- 5.3 Global Donafenib Tosylate Average Price by Type (2021-2032)
6 Market Segment by Application
- 6.1 Global Donafenib Tosylate Sales Quantity by Application (2021-2032)
- 6.2 Global Donafenib Tosylate Consumption Value by Application (2021-2032)
- 6.3 Global Donafenib Tosylate Average Price by Application (2021-2032)
7 North America
- 7.1 North America Donafenib Tosylate Sales Quantity by Type (2021-2032)
- 7.2 North America Donafenib Tosylate Sales Quantity by Application (2021-2032)
- 7.3 North America Donafenib Tosylate Market Size by Country
- 7.3.1 North America Donafenib Tosylate Sales Quantity by Country (2021-2032)
- 7.3.2 North America Donafenib Tosylate Consumption Value by Country (2021-2032)
- 7.3.3 United States Market Size and Forecast (2021-2032)
- 7.3.4 Canada Market Size and Forecast (2021-2032)
- 7.3.5 Mexico Market Size and Forecast (2021-2032)
8 Europe
- 8.1 Europe Donafenib Tosylate Sales Quantity by Type (2021-2032)
- 8.2 Europe Donafenib Tosylate Sales Quantity by Application (2021-2032)
- 8.3 Europe Donafenib Tosylate Market Size by Country
- 8.3.1 Europe Donafenib Tosylate Sales Quantity by Country (2021-2032)
- 8.3.2 Europe Donafenib Tosylate Consumption Value by Country (2021-2032)
- 8.3.3 Germany Market Size and Forecast (2021-2032)
- 8.3.4 France Market Size and Forecast (2021-2032)
- 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
- 8.3.6 Russia Market Size and Forecast (2021-2032)
- 8.3.7 Italy Market Size and Forecast (2021-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Donafenib Tosylate Sales Quantity by Type (2021-2032)
- 9.2 Asia-Pacific Donafenib Tosylate Sales Quantity by Application (2021-2032)
- 9.3 Asia-Pacific Donafenib Tosylate Market Size by Region
- 9.3.1 Asia-Pacific Donafenib Tosylate Sales Quantity by Region (2021-2032)
- 9.3.2 Asia-Pacific Donafenib Tosylate Consumption Value by Region (2021-2032)
- 9.3.3 China Market Size and Forecast (2021-2032)
- 9.3.4 Japan Market Size and Forecast (2021-2032)
- 9.3.5 South Korea Market Size and Forecast (2021-2032)
- 9.3.6 India Market Size and Forecast (2021-2032)
- 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
- 9.3.8 Australia Market Size and Forecast (2021-2032)
10 South America
- 10.1 South America Donafenib Tosylate Sales Quantity by Type (2021-2032)
- 10.2 South America Donafenib Tosylate Sales Quantity by Application (2021-2032)
- 10.3 South America Donafenib Tosylate Market Size by Country
- 10.3.1 South America Donafenib Tosylate Sales Quantity by Country (2021-2032)
- 10.3.2 South America Donafenib Tosylate Consumption Value by Country (2021-2032)
- 10.3.3 Brazil Market Size and Forecast (2021-2032)
- 10.3.4 Argentina Market Size and Forecast (2021-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Donafenib Tosylate Sales Quantity by Type (2021-2032)
- 11.2 Middle East & Africa Donafenib Tosylate Sales Quantity by Application (2021-2032)
- 11.3 Middle East & Africa Donafenib Tosylate Market Size by Country
- 11.3.1 Middle East & Africa Donafenib Tosylate Sales Quantity by Country (2021-2032)
- 11.3.2 Middle East & Africa Donafenib Tosylate Consumption Value by Country (2021-2032)
- 11.3.3 Turkey Market Size and Forecast (2021-2032)
- 11.3.4 Egypt Market Size and Forecast (2021-2032)
- 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
- 11.3.6 South Africa Market Size and Forecast (2021-2032)
12 Market Dynamics
- 12.1 Donafenib Tosylate Market Drivers
- 12.2 Donafenib Tosylate Market Restraints
- 12.3 Donafenib Tosylate Trends Analysis
- 12.4 Porters Five Forces Analysis
- 12.4.1 Threat of New Entrants
- 12.4.2 Bargaining Power of Suppliers
- 12.4.3 Bargaining Power of Buyers
- 12.4.4 Threat of Substitutes
- 12.4.5 Competitive Rivalry
13 Raw Material and Industry Chain
- 13.1 Raw Material of Donafenib Tosylate and Key Manufacturers
- 13.2 Manufacturing Costs Percentage of Donafenib Tosylate
- 13.3 Donafenib Tosylate Production Process
- 13.4 Industry Value Chain Analysis
14 Shipments by Distribution Channel
- 14.1 Sales Channel
- 14.1.1 Direct to End-User
- 14.1.2 Distributors
- 14.2 Donafenib Tosylate Typical Distributors
- 14.3 Donafenib Tosylate Typical Customers
15 Research Findings and Conclusion
16 Appendix
- 16.1 Methodology
- 16.2 Research Process and Data Source
Summary:
Get latest Market Research Reports on Donafenib Tosylate. Industry analysis & Market Report on Donafenib Tosylate is a syndicated market report, published as Global Donafenib Tosylate Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032. It is complete Research Study and Industry Analysis of Donafenib Tosylate market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
